Módulo 1 – Curso pós-graduado – VIH e Envelhecimento

Drug-drug Interactions and Polypharmacy in Older HIV Persons

As interações farmacológicas no contexto das alterações neurocognitivas


  1. Mushtaq R, Shoib S, Shah T, Mushtaq S. Relationship between loneliness, psychiatric disorders and physical health? A review on the psychological aspects of loneliness. J Clin Diagn Res. 2014;8(9):WE01-4.
  2. Dahlberg L, McKee KJ. Correlates of social and emotional loneliness in ol- der people: evidence from an English community study. Aging Ment Health. 2014;18(4):504-14.
  3. Price LH, Kao HT, Burgers DE, Carpenter LL, Tyrka AR. Telomeres and early-life stress: an overview. Biol Psychiatry. 2013;73(1):15-23.
  4. Franceschi C, Campisi J. Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases. J Gerontol A Biol Sci Med Sci. 2014;69 Suppl 1:S4-9.
  5. Guaraldi G, Prakash M, Moecklinghoff C, Stellbrink HJ. Morbidity in older HIV-infected patients: impact of long-term antiretroviral use. AIDS Rev. 2014;16(2):75-89.
  6. Almond M. Depression and inflammation: examining the link. Current Psychiatry. 2013;12(6):25-32.
  7. Hong S, Banks WA. Role of the immune system in HIV-associated neuroinflammation and neurocognitive implications. Brain Behav Immun. 2015 Mar;45:1-12.
  8. Cysique LA, Moffat K, Moore DM, et al. HIV, vascular and aging injuries in the brain of clinically stable HIV-infected adults: a (1)H MRS study. PLoS One. 2013;8(4):e61738.
  9. Smith RL, de Boer R, Brul S, Budovskaya Y, van Spek H. Premature and accelerated aging: HIV or HAART? Front Genet. 2013;3:328.
  10. Rodriguez-Penney AT, Iudicello JE, Riggs PK, et al. Co-morbidities in persons infected with HIV: increased burden with older age and negative effects on health-related quality of life. AIDS Patient Care STDS. 2013;27(1):5-16.
  11. New York State Department of Health (NYSDOH) AIDS Institute. Appendix II: Interactions between HIV-related medications and psychotropic medications. in HIV clinical guidelines – HIV and mental health. Updated April 2010. (disponível em http://www.hivguidelines.org/clinical-guidelines/hiv-and-mental-health/ appendix-ii-interactions-between-hiv-related-medications-and-psychotropic-medications/, acedido em 2016-03-15).
  12. Freudenreich O, Goforth HW, Cozza KL, et al.
  13. Psychiatric treatment of persons with HIV/AIDS: an HIV-psychiatry consensus survey of current practices. Psychosomatics. 2010;51(6):480-8.
  14. Weber E, Blackstone K, Woods SP. Cognitive neurorehabilitation of HIV- associated neurocognitive disorders: a qualitative review and call to action. Neuropsychol Rev. 2013;23(1):81-98.
  15. Coming of Age – a guide to ageing well with HIV. 2013 (disponível em http:// www.justri.org/COA-2013-web.pdf, acedido em 2015-07-14).
  16. Cross S, Onen N, Gase A, Overton ET, Ances BM. Identifying risk factors for HIV-associated neurocognitive disorders using the international HIV dementia scale. J Neuroimmune Pharmacol. 2013;8(5):1114–1122.
  17. Nightingale S, Winston A, Letendre S, et al. Controversies in HIV-associated neurocognitive disorders. Lancet Neurol. 2014;13(11):1139-51.
Logo MSD Termos de utilização | Política de Privacidade | Sobre a MSD Copyright © 2018 Todos os direitos reservados. Merck Sharp & Dohme Corp.,uma subsidiária da Merck & Co., Inc. Kenilworth, NJ, USA, conhecida fora dos EUA e Canadá como MSD. Os conteúdos disponibilizados nesta página Web são informação de carácter geral e não substituem em nenhum caso as consultas, tratamentos ou as recomendações do seu médico. INFC-1273571-0000 11/2018